EUCCAT works towards a model of decentralised GMP production in specialised hospitals that combine high quality clinical care with clinical and fundamental research. These centres have the expertise in precision medicine that is needed for an efficient evaluation and clinical use of these therapies. This decentralised production model will be complimentary to the existing models of centralised production and would focus primarily on small volume or individualised therapies.

EUCCAT will also strive to facilitate the development of academia-developed therapies into clinical applications. The current regulatory and financial context does not sufficiently facilitate the clinical development of academia-developed therapies; however, EUCCAT believes that a larger input of academia-developed therapies will ultimately benefit all stakeholders and first and foremost the patients. The combined patient access and expertise of EUCCAT’s members will also allow the development of therapies for small-volume diseases. To this end, EUCCAT is experimenting with new models for clinical development based on a collaboration between specialized hospital centres and based on the principles of cost-sharing, fair reward, and ethical pricing.